The antibiotic that doctors say you should never take unless absolutely necessary belongs to a class called fluoroquinolones — sold under familiar brand names like Cipro, Levaquin, and Avelox. These drugs carry the FDA’s most severe warning label, a Black Box Warning, and have been linked to tendon rupture, permanent nerve damage, dangerous blood sugar crashes, aortic tears, and serious mental health effects including confusion, hallucinations, and psychosis. For older adults, particularly those already navigating cognitive decline or dementia care, these risks demand serious attention. The FDA itself has stated plainly that fluoroquinolones should not be used as a first-line treatment for common infections like uncomplicated urinary tract infections, sinusitis, or bronchitis — conditions for which safer alternatives exist.
Yet millions of prescriptions are still written each year. Consider a 72-year-old woman prescribed Cipro for a routine UTI who then develops Achilles tendon pain so severe she can barely walk, compounding the mobility challenges she already faces from mild cognitive impairment. Stories like hers are not rare. This article breaks down exactly why these antibiotics are so problematic, who faces the greatest risk, what the FDA warnings actually say, and what you or your loved one’s doctor should prescribe instead.
Table of Contents
- Why Do Doctors Say Fluoroquinolones Should Never Be Your First Antibiotic Choice?
- The Full Timeline of FDA Black Box Warnings and What They Mean for Older Adults
- Tendon Rupture and Nerve Damage — The Risks That Hit Seniors Hardest
- What to Ask Your Doctor to Prescribe Instead
- Antibiotic Resistance — The Hidden Crisis Making This Problem Worse
- Recognizing Fluoroquinolone Side Effects in Dementia Patients
- Where Fluoroquinolone Policy Is Heading
- Conclusion
- Frequently Asked Questions
Why Do Doctors Say Fluoroquinolones Should Never Be Your First Antibiotic Choice?
Fluoroquinolones — ciprofloxacin, levofloxacin, and moxifloxacin — are broad-spectrum antibiotics, meaning they kill a wide range of bacteria. That power made them popular for decades. Doctors prescribed them for everything from sinus infections to urinary tract infections to bronchitis flare-ups. But the accumulating evidence of harm has been so significant that the FDA took the unusual step of issuing multiple safety communications over a ten-year period, each one adding new warnings. By May 2016, the agency’s position was unambiguous: the risks outweigh the benefits for uncomplicated infections where other antibiotics will do the job. The problem is not that fluoroquinolones never work or should never be used at all.
For serious, life-threatening infections — certain types of pneumonia, complicated intra-abdominal infections, or cases where bacteria are resistant to every other available antibiotic — they remain a legitimate tool. The problem is proportionality. The CDC estimates that roughly 30 percent of the 211 million outpatient antibiotic prescriptions written in the United States each year are unnecessary. When a fluoroquinolone is handed out for a mild sinus infection that would resolve on its own or respond to a safer drug like amoxicillin, the patient takes on real risk for no meaningful benefit. For comparison, consider the difference between using a standard antibiotic like nitrofurantoin for an uncomplicated UTI versus reaching for ciprofloxacin. Nitrofurantoin targets urinary tract bacteria specifically, carries far fewer systemic side effects, and does not come with a Black Box Warning. Ciprofloxacin, by contrast, exposes the patient to the full menu of fluoroquinolone risks — tendon damage, nerve damage, mental health effects — for an infection that the simpler drug handles just as effectively.
The Full Timeline of FDA Black Box Warnings and What They Mean for Older Adults
The FDA does not issue Black Box Warnings lightly. It is the agency’s strongest safety alert, reserved for drugs with risks serious enough to cause permanent harm or death. Fluoroquinolones have accumulated an extraordinary number of these warnings over the past two decades, each reflecting a distinct category of harm that clinical evidence forced the agency to acknowledge. The timeline tells the story. In July 2008, the FDA added its first Black Box Warning for tendinitis and tendon rupture. In August 2013, it required new label language about irreversible peripheral neuropathy — nerve damage that can be permanent and can strike at any point during treatment, not just after prolonged use.
May 2016 brought the landmark guidance that these drugs should not be used for uncomplicated sinusitis, bronchitis, or UTIs at all. Then in July 2018, the FDA flagged two more categories of harm: dangerous drops in blood sugar and serious mental health side effects, including confusion, hallucinations, and psychosis. Finally, in December 2018, the agency warned that fluoroquinolones roughly double the risk of aortic aneurysm and aortic dissection — tears in the body’s main artery that can be fatal. For older adults, especially those with dementia or cognitive impairment, these warnings carry extra weight. However, the mental health side effects deserve particular scrutiny in this population. Confusion and hallucinations caused by a fluoroquinolone can easily be mistaken for a worsening of dementia symptoms, leading caregivers and even physicians down the wrong diagnostic path. A patient whose sudden confusion is actually a drug reaction might have their dementia medications adjusted unnecessarily, while the real culprit — the antibiotic — continues doing damage. If your loved one experiences sudden changes in cognition or behavior after starting any antibiotic, the medication itself should be investigated as a possible cause.
Tendon Rupture and Nerve Damage — The Risks That Hit Seniors Hardest
The physical side effects of fluoroquinolones fall hardest on the people least able to recover from them. Research shows that fluoroquinolone users face a 3.14 times increased risk of Achilles tendon rupture compared to non-users, and that elevated risk persists for 60 days after stopping the drug. The highest-risk group is adults aged 60 and older who are also taking corticosteroids — a common combination, since many older adults use steroids for conditions like arthritis or COPD. In that group, the rate climbs to 19.6 tendon ruptures per 10,000 patients. An analysis of the FDA’s Adverse Event Reporting System from 2016 through 2021 documented 35,667 fluoroquinolone-associated adverse events, including 1,771 cases of tendonitis and 1,018 tendon ruptures. Ciprofloxacin showed the strongest association with tendonitis, while levofloxacin was most strongly linked to outright tendon rupture.
About 66 percent of patients recovered within 15 to 30 days of stopping the drug, but roughly 10 percent of cases resulted in long-term complications — persistent swelling, pain, and difficulty walking. For someone caring for a parent with Alzheimer’s disease, imagine the consequences of a tendon rupture. A person who was previously mobile enough to walk to the bathroom independently is now immobilized, needing surgery or weeks in a boot, losing muscle mass and functional ability that may never fully return. Falls are already the leading cause of injury-related death in adults over 65. Adding a drug-induced tendon injury to that equation can be the event that tips a person from living at home to requiring full-time facility care. Peripheral neuropathy — the nerve damage that the FDA flagged in 2013 — compounds the problem further, because it can be permanent and affects balance, sensation in the feet, and the ability to detect pain, all of which increase fall risk.
What to Ask Your Doctor to Prescribe Instead
The good news is that for most common infections where fluoroquinolones get prescribed, effective and safer alternatives exist. The conversation with your doctor does not need to be adversarial — most physicians are well aware of the FDA warnings and will appreciate a patient or caregiver who asks informed questions. For uncomplicated urinary tract infections, nitrofurantoin and trimethoprim-sulfamethoxazole are first-line options recommended by infectious disease guidelines. For bacterial sinusitis that genuinely requires antibiotics — most sinus infections are viral and do not — amoxicillin-clavulanate is the standard choice. For acute bronchitis exacerbations in patients with COPD, doxycycline or azithromycin are typically appropriate.
Each of these carries its own side effect profile, but none comes with the cascade of Black Box Warnings attached to fluoroquinolones. The tradeoff is clear: comparable effectiveness for the target infection, dramatically lower risk of catastrophic side effects. However, there are situations where fluoroquinolones remain the right call, and it is important not to refuse them reflexively. Certain complicated urinary infections, some types of bacterial pneumonia requiring hospitalization, and infections caused by bacteria resistant to all other available antibiotics may genuinely require a fluoroquinolone. The key question to ask is straightforward: “Is there a safer antibiotic that would work for this infection?” If the answer is yes, take the safer option. If the answer is no, then the fluoroquinolone is being used as intended — for a situation where its benefits outweigh its documented risks.
Antibiotic Resistance — The Hidden Crisis Making This Problem Worse
Beyond the direct side effects, fluoroquinolone overuse is fueling a resistance crisis that threatens to make these drugs useless precisely when they are needed most. A study of E. coli infections in U.S. veterans across seven Midwest states, using data from 2010 through 2023, found that 29.4 percent of E. coli infections were already resistant to fluoroquinolones. Globally, the picture is even grimmer — in some countries, up to 82 percent of E. coli infections show fluoroquinolone resistance. This matters for older adults and dementia patients in a very specific way. Urinary tract infections are among the most common infections in elderly populations, particularly in women and in people with catheters or incontinence.
E. coli causes the majority of UTIs. If fluoroquinolone resistance continues to climb because these drugs are overprescribed for mild infections, they may stop working for the serious, complicated UTIs where they are genuinely needed. The CDC’s Antibiotic Stewardship Initiative, with its most recent update published in February 2026, continues to push for reduced unnecessary prescribing — but progress depends on both physicians and patients understanding why restraint matters. A limitation worth acknowledging: resistance patterns vary by region, hospital, and even individual patient history. A fluoroquinolone that would fail against resistant bacteria in one city might still be effective in another. This is why culture and sensitivity testing — where a lab identifies exactly which bacteria are causing an infection and which drugs will kill them — is so valuable, especially for older patients with recurrent infections. Do not assume any antibiotic will work. Ask for a culture.
Recognizing Fluoroquinolone Side Effects in Dementia Patients
One of the most dangerous aspects of fluoroquinolone side effects in people with dementia is that the symptoms can masquerade as disease progression. A patient who suddenly becomes more confused, agitated, or begins hallucinating after starting Cipro or Levaquin may be experiencing a drug reaction — not a worsening of their Alzheimer’s or vascular dementia. Caregivers and family members are often the first to notice these changes, and their observations can be critical.
Keep a written log of any new medications started and the dates of any behavioral or cognitive changes. If a fluoroquinolone is prescribed and you notice new confusion, agitation, paranoia, or hallucinations within days of starting it, contact the prescribing physician immediately and specifically ask whether the antibiotic could be the cause. The mental health side effects flagged by the FDA in its July 2018 warning — confusion, hallucinations, psychosis — are not subtle when they occur, but they are easy to misattribute in someone who already has a cognitive diagnosis.
Where Fluoroquinolone Policy Is Heading
The trajectory of fluoroquinolone regulation has been consistently toward greater restriction, and there is no reason to expect that trend to reverse. Each round of FDA warnings has narrowed the appropriate use cases for these drugs, and the growing body of antibiotic resistance data strengthens the argument for further limits. The CDC’s ongoing stewardship efforts, hospital formulary restrictions, and increasing awareness among both physicians and patients are all pushing in the same direction.
For families managing dementia care, the practical takeaway is straightforward: be an informed advocate. Know that fluoroquinolones exist, know their brand names, and know that safer alternatives are available for most common infections. The day may come when a fluoroquinolone is genuinely the only option — and on that day, it should be used. But that day should come only after every safer alternative has been considered and ruled out.
Conclusion
Fluoroquinolone antibiotics — Cipro, Levaquin, and Avelox — carry the FDA’s most serious warning label and have been linked to tendon rupture, permanent nerve damage, aortic tears, dangerous blood sugar drops, and psychiatric effects including confusion and hallucinations. The FDA has stated explicitly that these drugs should not be first-line treatment for routine infections like uncomplicated UTIs, sinusitis, or bronchitis. For older adults, particularly those with dementia or cognitive impairment, the risks are amplified: tendon injuries can end independent mobility, nerve damage increases fall risk, and psychiatric side effects can be mistaken for disease progression.
The single most important step you can take is to ask one question every time an antibiotic is prescribed for yourself or your loved one: “Is there a safer alternative that would work for this infection?” In most cases, the answer is yes. Nitrofurantoin for UTIs, amoxicillin-clavulanate for sinusitis, doxycycline for bronchitis — these are proven, effective options without the severe risk profile. Keep a current medication list, request cultures for recurrent infections, and do not hesitate to ask why a fluoroquinolone is being chosen over a safer drug. Informed patients and vigilant caregivers are the most effective check against unnecessary prescribing.
Frequently Asked Questions
Are fluoroquinolones banned?
No. Fluoroquinolones remain FDA-approved and available by prescription. However, the FDA has issued multiple Black Box Warnings and explicitly advised that they should not be used as first-line treatment for uncomplicated UTIs, sinusitis, or bronchitis. They are reserved for serious infections where safer alternatives are not available.
What should I do if my loved one with dementia is prescribed Cipro or Levaquin?
Ask the prescribing doctor whether a safer antibiotic would be effective for the specific infection being treated. If a fluoroquinolone is deemed necessary, monitor closely for sudden changes in confusion, agitation, hallucinations, or mood — these are documented psychiatric side effects that can mimic dementia progression.
How long do fluoroquinolone side effects last?
Many patients recover within 15 to 30 days of stopping the drug. However, approximately 10 percent of cases involving tendon damage result in long-term complications. Peripheral neuropathy — nerve damage causing tingling, numbness, or pain — can be permanent.
Can a single dose of a fluoroquinolone cause tendon damage?
Yes. The FDA warnings do not specify a minimum duration of use before side effects can occur. Tendon damage and peripheral neuropathy have been reported with short courses and even early in treatment. The elevated risk of Achilles tendon rupture persists for 60 days after the last dose.
Why do doctors still prescribe fluoroquinolones for UTIs?
Habit, convenience, and the fact that fluoroquinolones are effective against a broad range of bacteria all play a role. In some cases, a culture may show that the specific bacteria causing the infection is resistant to first-line antibiotics but susceptible to a fluoroquinolone. The problem is not that these drugs are never appropriate — it is that they are prescribed far more often than the clinical situation warrants.
